ReviewPsoriasis (Auckland, N.Z.)2016
Management of scalp psoriasis: current perspectives.
Review in Psoriasis (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06771648 (A Prospective, Single-arm, Open-label, Post-market Clinical Follow-up Investigation to Verify Performance and Safety of Daxxin Psoriasis Shampoo When Used for Treatment of Moderate Scalp Psoriasis), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Single-arm, Open-label, Post-market Clinical Follow-up Investigation to Verify Performance and Safety of Daxxin Psoriasis Shampoo When Used for Treatment of Moderate Scalp Psoriasis
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.Dermatology and therapy · 2026Article
- Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).Dermatology and therapy · 2026Article
- Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study.Journal of clinical medicine · 2026Article
- Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.Dermatology and therapy · 2026Article
- Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Review
- Treatment of Recalcitrant Scalp Psoriasis with Topical Roflumilast Cream 0.3%: A Case Report.The Journal of clinical and aesthetic dermatology · 2025Article
- Biologic and Non-Biologic Therapies for Scalp Psoriasis: A Network Meta-analysis of Randomized Controlled Trials.Dermatology practical & conceptual · 2025Review
- Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease.Life (Basel, Switzerland) · 2025Review
- Updates on Psoriasis in Special Areas.Journal of clinical medicine · 2024Review
- A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (EnstilarDrugs in context · 2024Review
- An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.Current drug targets · 2024Review
- Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology.Clinical, cosmetic and investigational dermatology · 2024Article
- Line-field confocal optical coherence tomography imaging findings of scalp psoriasis.JAAD case reports · 2023Article
- Effectiveness of mixture of aspirin and ethanol regimen in the management of geographic tongue: a prospective study.Annals of medicine and surgery (2012) · 2023Article
- Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.Journal of clinical medicine · 2023Article
- Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.The Journal of clinical and aesthetic dermatology · 2023Review
- Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies.Postepy dermatologii i alergologii · 2023Article
- Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study).Dermatology (Basel, Switzerland) · 2023Observational
- Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.Dermatology and therapy · 2022Review
- Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.RSC advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory condition. The age of onset, chronicity, physical, and psychosocial consequences of the disease cause psoriasis to have a significant impact on patient quality of life. Scalp psoriasis is no different, and effective treatment results in an improvement in quality of life. Successful management of scalp psoriasis includes topical therapies that are acceptable to the patient for mild-to-moderate disease, and systemic therapies for recalcitrant or moderate-to-severe disease. The most effective topical therapies are corticosteroid products, or combination products with calcipotriol and corticosteroid. Newer vehicle options provide more attractive and pleasing products for patients and may improve adherence. The current perspectives for management of scalp psoriasis are discussed including available data for systemic therapy of severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.